European Heart Journal Advance Access originally published online on January 6, 2005
European Heart Journal 2005 26(6):590-597; doi:10.1093/eurheartj/ehi092
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death
1Utrecht Institute for Pharmaceutical Sciences (UIPS), Department of Pharmacoepidemiology and Pharmacotherapy, PO Box 80082, 3508 TB Utrecht, The Netherlands
2Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands
3The Uppsala Monitoring Centre, Uppsala, Sweden
Received 22 September 2004; revised 3 November 2004; accepted 25 November 2004; online publish-ahead-of-print 6 January 2005.
* Corresponding author. Tel: +31 30 253 7322; fax:+31 30 253 9166. E-mail address: m.l.debruin{at}pharm.uu.nl
See page 536 for the editorial comment on this article (doi:10.1093/eurheartj/ehi155)
Aims Drug-induced QTc-prolongation, resulting from inhibition of HERG potassium channels may lead to serious ventricular arrhythmias and sudden death. We studied the quantitative anti-HERG activity of pro-arrhythmic drugs as a risk factor for this outcome in day-to-day practice.
Methods and results All 284 426 case reports of suspected adverse drug reactions of drugs with known anti-HERG activity received by the International Drug Monitoring Program of the World Health Organization (WHO-UMC) up to the first quarter of 2003, were used to calculate reporting odds ratios (RORs). Cases were defined as reports of cardiac arrest, sudden death, torsade de pointes, ventricular fibrillation, and ventricular tachycardia (n=5591), and compared with non-cases regarding the anti-HERG activity, defined as the effective therapeutic plasma concentration (ETCPunbound) divided by the HERG IC50 value, of suspected drugs. We identified a significant association of 1.93 (95% CI: 1.89–1.98) between the anti-HERG activity of drugs, measured as log10 (ETCPunbound/IC50), and reporting of serious ventricular arrhythmias and sudden death to the WHO-UMC database.
Conclusion Anti-HERG activity is associated with the risk of reports of serious ventricular arrhythmias and sudden death in the WHO-UMC database. These findings are in support of the value of pre-clinical HERG testing to predict pro-arrhythmic effects of medicines.
Key Words: Adverse drug reaction reporting systems • Arrhythmia • Potassium channels • Pre-clinical drug evaluation • Sudden death • Torsades de pointes
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- The degree of potassium channel blockade and the risk of torsade de pointes: the truth, nothing but the truth, but not the whole truth
- Sami Viskin and Uri Rosovski
EHJ 2005 26: 536-537.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  B. Darpo Detection and reporting of drug-induced proarrhythmias: room for improvement Europace, September 1, 2007; 9(suppl_4): iv23 - iv36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wisialowski, K. Crimin, J. Engtrakul, J. O'Donnell, B. Fermini, and A. A. Fossa Differentiation of Arrhythmia Risk of the Antibacterials Moxifloxacin, Erythromycin, and Telithromycin Based on Analysis of Monophasic Action Potential Duration Alternans and Cardiac Instability J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 352 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Viskin and U. Rosovski The degree of potassium channel blockade and the risk of torsade de pointes: the truth, nothing but the truth, but not the whole truth Eur. Heart J., March 2, 2005; 26(6): 536 - 537. [Full Text] [PDF]
|
|